Status:
UNKNOWN
Routine Staple Line Reinforcement for Minimally Invasive Distal Pancreatectomy
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Pancreas Neoplasm
Stump
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Postoperative fistula is the major complications of distal pancreatectomies which prohibit patients' recovery. Previous studies have reported controversial results regarding the efficacy of pancreatic...
Detailed Description
Distal pancreatectomy (DP)is the standard surgical method for benign or malignant pancreatic tumors locating at body and tail \[1\]. Clinically relevant postoperative pancreatic fistula (CR-POPF) is t...
Eligibility Criteria
Inclusion
- Those who will receive distal pancreatectomy via minimally invasive approaches, no matter benign or malignant;
- Aged from 18 - 80 years;
- Preoperative diagnosis of serous or mucinous cystic adenoma;
- Preoperative diagnosis of solid pseudopapillary tumor (SPT);
- Preoperative diagnosis of neuroendocrine tumor;
- Preoperative diagnosis of intraductal papillary mucinous neoplasm (IPMN);
- Preoperative diagnosis of or pseudocyst;
- Preoperative diagnosis of distal pancreatic malignancies;
- Patients willing to provide informed consent.
Exclusion
- History of upper abdominal surgical history such as splenectomy, gastrectomy, liver resection, duodenal or pancreatic resection (not including laparoscopic cystectomy);
- Pancreatic trauma;
- With pneumoperitoneum contraindications;
- With severe heart or pulmonary diseases which is not fit for surgeries.
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 30 2023
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT04663789
Start Date
December 1 2020
End Date
May 30 2023
Last Update
February 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730